• Publications
  • Influence
Emodin Regulates Bone Remodeling by Inhibiting Osteoclastogenesis and Stimulating Osteoblast Formation
TLDR
It is shown here that emodin is a potential target for osteoporosis therapeutics, as treatment with this agent enhances osteoblast differentiation and bone growth and suppresses osteoclast differentiate and bone resorption. Expand
Purslane suppresses osteoclast differentiation and bone resorbing activity via inhibition of Akt/GSK3β-c-Fos-NFATc1 signaling in vitro and prevents lipopolysaccharide-induced bone loss in vivo.
TLDR
Purslane could exhibit its anti-osteoclastogenic activity by inhibiting Akt/GSK3β-c-Fos-NFATc1 signaling cascades, and is a potential natural medicine for the treatment of osteoclast-related diseases. Expand
Claudin 11 regulates bone homeostasis via bidirectional EphB4-EphrinB2 signaling
TLDR
It is demonstrated that Cldn11 is a potential target for bone disease therapeutics as a dual modulator of osteogenesis enhancement and osteoclastogenesis inhibition and a novel regulator in bone homeostasis. Expand
Nicotinamide phosphoribosyltransferase inhibits receptor activator of nuclear factor-κB ligand-induced osteoclast differentiation in vitro
TLDR
It is demonstrated that Nampt acts as a negative regulator of RANKL-mediated differentiation of BMMs into osteoclasts, suggesting the potential therapeutic targets to treat bone-related disorders such as osteoporosis. Expand
Progranulin and a Five Transmembrane Domain-Containing Receptor-like Gene Are the Key Components in Receptor Activator of Nuclear Factor κB (RANK)-dependent Formation of Multinucleated Osteoclasts*
TLDR
A new axis in the formation of multinucleated cells via RANK signaling: the progranulin (PGRN)-induced receptor-like gene during osteoclastogenesis is introduced, which may offer a novel therapeutic modality for osteoporosis and other bone-associated diseases. Expand
Dual Effect of Chrysanthemum indicum Extract to Stimulate Osteoblast Differentiation and Inhibit Osteoclast Formation and Resorption In Vitro
TLDR
Investigation of Chrysanthemum indicum extract (CIE) on the differentiation of osteoclastic and osteoblastic cells revealed that CIE could have a potential therapeutic role in bone-related disorders through its dual effects on osteoclast and osteoblast differentiation. Expand
Oleanolic acid acetate inhibits osteoclast differentiation by downregulating PLCγ2-Ca(2+)-NFATc1 signaling, and suppresses bone loss in mice.
TLDR
Results suggested that OAA inhibited RANKL-mediated osteoclastogenesis via PLCγ2-Ca(2+)-NFATc1 signaling in vitro and suppressed inflammatory bone loss in vivo. Expand
Esculetin attenuates receptor activator of nuclear factor kappa-B ligand-mediated osteoclast differentiation through c-Fos/nuclear factor of activated T-cells c1 signaling pathway.
TLDR
The results indicate for the first time that esculetin inhibits RANKL-mediated osteoclastogenesis via direct suppression of c-Fos and NFATc1 expression and exerts an inhibitory effect on actin ring formation during osteOClastogenesis. Expand
Parthenolide inhibits osteoclast differentiation and bone resorbing activity by down-regulation of NFATc1 induction and c-Fos stability, during RANKL-mediated osteoclastogenesis
TLDR
Parthenolide inhibits the differentiation and bone-resolving activity of osteoclast by RANKL, suggesting its potential therapeutic value for bone destructive disorders associated with osteocline-mediated bone resorption. Expand
Costunolide Inhibits Osteoclast Differentiation by Suppressing c‐Fos Transcriptional Activity
TLDR
It is found that costunolide significantly inhibited RANKL‐induced BMM differentiation into osteoclasts in a dose‐dependent manner without affecting cytotoxicity and the inhibitory effects of costunolate were rescued by overexpression of constitutively active (CA)‐NFATc1. Expand
...
1
2
3
4
...